Cellectis S.A.: Clinical Trials

6 trials sponsored by Cellectis S.A., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 terminated, 1 recruiting, 1 withdrawn. 6 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Active not recruiting 2, Terminated 2, Recruiting 1, Withdrawn 1
Phase 22Active not recruiting 1, Recruiting 1

Follow Cellectis S.A.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
UCART20x22, CLLS52 - B-cell Non-Hodgkin Lymphoma (B-NHL)
Phase 1 / Phase 2RecruitingCellectis S.A.802022-11-012025-08-24
Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)
UCARTCS1A - Relapsed/Refractory Multiple Myeloma
Phase 1TerminatedCellectis S.A.112019-11-212023-09-22
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
UCART22, CLLS52 - B-cell Acute Lymphoblastic Leukemia
Phase 1 / Phase 2Active not recruitingCellectis S.A.452019-10-142026-11-09
Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia
UCART123 - Acute Myeloid Leukaemia
Phase 1WithdrawnCellectis S.A.2019-07-112020-07-14
Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN
UCART123 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase 1TerminatedCellectis S.A.12017-06-282019-07-31
Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
UCART123v1.2 - Relapsed/Refractory Acute Myeloid Leukemia
Phase 1Active not recruitingCellectis S.A.292017-06-192025-08-07

Conditions studied

Leukemia, Myeloid, Acute (2)  ·  Recurrence (2)  ·  Blastic Plasmacytoid Dendritic Cell Neoplasm (1)  ·  Burkitt Lymphoma (1)  ·  Hematologic Neoplasms (1)  ·  Lymphoma, B-Cell (1)  ·  Multiple Myeloma (1)

Interventions

Alemtuzumab (2)

Countries

United States (5)  ·  France (2)  ·  Spain (1)

Top investigators

Gail Roboz, Dr (1)  ·  Ghulam Mufti, Pr (1)  ·  Ioana Kloos, MD (1)  ·  Jeremy Abramson, MD (1)  ·  Nitin Jain, MD (1)